Status:
COMPLETED
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Diabetic Peripheral Neuropathic Pain (DPN)
Postherpetic Neuralgia (PHN)
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral ...
Eligibility Criteria
Inclusion
- Patients who are diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
Exclusion
- Severe Pain associated with conditions other than Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, Human Immunodeficiency virus related peripheral neuropathy, and chemotherapy induced peripheral neuropathy that may confound assessment or self evaluation of the neuropathic pain.
- Skin Condition in the affected dermatome that (in the judgment of the investigator) could alter sensation.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00407511
Start Date
January 1 2007
End Date
July 1 2008
Last Update
February 9 2021
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
2
Pfizer Investigational Site
Quito, Pichincha, Ecuador
3
Pfizer Investigational Site
Tijuana, B. C., Mexico, 22010
4
Pfizer Investigational Site
Mexicali, B.C., Mexico, 21100